Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis-Reference-Cited by-同舟云学术

Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis

Published:2021-10 Issue: Volume:519 Page:141-149
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Zhao Wen,Yu Danlei,Chen Zhen,Yao Weilong,Yang Jin,Ramalingam Suresh S.,Sun Shi-Yong^ORCID

Funder

Winship Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference34 articles.

1. Cancer statistics, 2020;Siegel;Ca - Cancer J. Clin.,2020

2. Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer;Carlisle;Future Oncol.,2019

3. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review;Piper-Vallillo;J. Clin. Oncol.,2020

4. MEK5/ERK5 pathway: the first fifteen years;Drew;Biochim. Biophys. Acta,2012

5. Components of a new human protein kinase signal transduction pathway;Zhou;J. Biol. Chem.,1995

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ERK5 mediates pro-tumorigenic phenotype in non-small lung cancer cells induced by PGE2;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2024-10

2. Long-term survival in a patient with metastatic parathyroid carcinoma harboring an EGFR sensitizing mutation: a case report;Journal of International Medical Research;2024-07

3. Bone and Extracellular Signal-Related Kinase 5 (ERK5);Biomolecules;2024-05-04

4. ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression;Neoplasia;2023-08

5. Case report: Long-term survival with anlotinib in a metastatic parathyroid carcinoma patient harboring EGFR-sensitizing mutation;2023-07-10